...sorry, my last post on this topic.  It turns out I forgot some of my older posts.  Specifically, Farxiga (Astra Zeneca).  It is an SGLT2i, and it was halted early due to overwhelming efficacy for both T2D patients and non-T2D patients (I think it was then approved??? could be wrong).  Any way, it is NOT recommended for patients with eGFR < 45, and it is "contrindicated" for patients with eGFR < 30.  I think we would blow them out of the water in both MACE for ALL CKD patients (both T2D and non-T2D), AND we would be especially helpful in patients with eGFR < 45.  AZN needs to take out RVX

https://twitter.com/GideonHealth/status/1244546213095112704

https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacy-in-patients-with-chronic-kidney-disease.html